- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Approves Medtronic’s MRI-Friendly Pacemaker
The FDA has approved the Advisa DR MRI SureScan pacing system, a second-generation pacemaker designed for use with MRI machines, according to Medtronic.
The FDA has approved the Advisa DR MRI SureScan pacing system, a second-generation pacemaker designed for use with MRI machines, according to device maker Medtronic.
Advisa MRI was specifically tested and approved for use as labeled with MRI scanners in the U.S. According to Medtronic, 156 patients were scanned in a clinical trial for the device and none showed MRI-related complications.
The new system includes an Advisa MRI device and two CapSureFix MRI SureScan leads, which must be used together.
“Your physician can implant a pacemaker with advanced options that will allow for broad access to MRI scanning,” J. Rod Gimbel, MD, of Cardiology Associates of East Tennessee in Knoxville, Tenn, said in a release from Medtronic.
Medtronic introduced the first SureScan pacemaker system in Europe in 2008, and more than 100,000 SureScan devices have been sold worldwide. In the U.S., an estimated more than 10 percent of patient with SureScan systems have received MRIs, the company said.
Advisa MRI pacing system includes a Managed Ventricular Pacing algorithm to reduce unnecessary ventricular pacing, complete capture management to automatically test and adjust the energy supplied to the heart, higher upper tracking rates to allow the pacemaker to keep up with quicker heart rates, and rate drop response to reduce frequency of fainting in patients.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
